Dolutegravir and lamivudine have been approved by the US FDA as the first fixed-dose, complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults with no antiretroviral treatment history and with no known or suspected substitutions associated with resistance to the individual components of the drug.

Currently, the standard of care for patients who have never been treated is a 3-drug regimen.

With this approval, patients who have never been treated have the option of taking a two-drug regimen in a single tablet while eliminating additional toxicity and potential drug interactions from a third drug.

Patients infected with both HIV and hepatitis B should add additional treatment for their hepatitis B or consider a different drug regimen.

Dr KK Aggarwal

Padma Shri Awardee

President Elect Confederation of Medical Associations in Asia and Oceania   (CMAAO)

Group Editor-in-Chief IJCP Publications

President Heart Care Foundation of India

Past National President IMA